HUNTSMAN CORP. DL-,01/ US4470111075 /
| 2024-10-18 8:03:11 AM | Chg. 0.0000 | Volume | Bid4:49:17 PM | Ask9:46:36 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 21.4000EUR | 0.00% | 0 Turnover: 0.0000 |
-Bid Size: - | -Ask Size: - | 3.94 bill.EUR | - | - |
GlobeNewswire
08-14
Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
GlobeNewswire
08-13
The American Fuel & Petrochemical Association Recognizes BrandSafway with 44 Awards
GlobeNewswire
06-27
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Base...
GlobeNewswire
06-12
Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches S...
GlobeNewswire
06-03
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-li...
GlobeNewswire
05-21
Savile Row Showcase: Broad Arrow Presents its Latest Private Sales Offering, A Handsome 1963 Mercede...
GlobeNewswire
05-16
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benef...
GlobeNewswire
05-14
Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update
GlobeNewswire
05-07
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
04-24
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B...
GlobeNewswire
04-16
FountainRx Selects Inovalon’s ScriptMed® Software To Enhance Patient Care and Scale Specialty and In...
GlobeNewswire
04-09
Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursem...
GlobeNewswire
03-28
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operatio...
GlobeNewswire
02-28
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Fi...
GlobeNewswire
02-14
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focu...
GlobeNewswire
02-06
Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth...
GlobeNewswire
01-08
Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of...
GlobeNewswire
2023-12-29
Visionary Leadership: HMG Strategy, the World’s #1 Executive Leadership Network, Looks Ahead to its ...
GlobeNewswire
2023-11-29
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obs...
GlobeNewswire
2023-11-27
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2023-11-14
Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update
GlobeNewswire
2023-11-10
Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer
